A. Karlowsky M. Holliday K. Luther M. Rybak B. Killian

151 TUESDAY SCIENTIFIC SESSIONS Final Program D-1458 Chemotherapy-Induced Changes of the Intestinal Micro- biota Analyzed by High Throughput Pyrosequencing

E. Montassier

1 , E. Batard 1 , J. Hardouin 2 , J. Caillon 1 , T. Carton 3 , N. Caroff 1 , T. Gastinne 1 , P. Moreau 1 , G. Potel 1 , M. De la Cochetière 2 , F. Le Vacon 3 ; 1 Ctr. Hosp. Univ. de Nantes, Nantes, France, 2 Faculté de Med. de Nantes, Nantes, France, 3 Biofortis Res., Nantes, France. D-1459 Pyrotyping: A Practical Genotyping Method Compatible to Multilocus Sequence Typing MLST by Pyrosequencing

T. Saga, N. Aoike, Y. Ishii, K. Tateda; Toho Univ., Tokyo, Japan. D-1460

Rapid Identification of Causative Bacteria from Positive Blood Culture Samples by DNA Pyrosequencing

M. Yamada, K. Yanagihara, Y. Morinaga, S. Kohno, S. Kamihira; Nagasaki Univ., Nagasaki, Japan.

D-1461 A Novel TM-Mapping Method that Enables Identification of Pathogenic Microorganisms Within 3 Hours after Samples are Collected

H. Niimi

1 , T. Ueno 1 , S. Hayashi 1 , M. Mori 2 , H. Tabata 3 , H. Minami 3 , S. Saito 1 , I. Kitajima 1 ; 1 Toyama Univ. Hosp., Toyama, Japan, 2 Ishikawa Prefectural Univ., Ishikawa, Japan, 3 Hokkaido Mitsui Chemicals Corp., Hokkaido, Japan. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 173 E Poster Session In Vitro Activity of Lipoglycopeptides and Related Compounds Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: E-1462 In Vitro Activity of Oritavancin against Gram-Positive Pathogens Isolated in Canadian Hospitals in 2011

J. A. Karlowsky

1,2 , H. Adam 1 , M. Baxter 2 , D. Hoban 1,2 , G. G. Zhanel 2 ; 1 Diagnostic Services of Manitoba, Winnipeg, Canada, 2 Univ. of Manitoba, Winnipeg, Canada. E-1463 A Multi-Site Study Comparing an 18-24h Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method for Oritavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms

N. M. Holliday

1 , D. Zollos 1 , C. C. Knapp 1 , S. B. Killian 1 , F. F. Arhin 2 , G. Moeck 2 , J. M. Streit 3 , R. N. Jones 3 , R. R. Prochaska 3 , P. R. Rhomberg 3 , L. Sykes 4 ; 1 TREK Diagnostic Systems, Cleveland, OH, 2 The Med. Com- pany, Parsippany, NJ, 3 JMI Lab., North Liberty, IA, 4 Kaiser Permanente, Cleveland, OH. E-1464 Evaluating the Activity of Daptomycin DAP and Linezolid LND in Combination with Rifampin RIF or Gentamicin GENT on Enterococcus faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations SEV

M. K. Luther